HIF1A and rectal cancer: Toiyama et al. reported that a low gene expression level of HIF1A in pre-treatment tumor biopsies was significantly associated with a high rate of tumor regression in patients with rectal cancer treated with neoadjuvant 5-FU-based CRT [45].